Patients must have pathologically (histologically or cytologically) proven diagnosis of MCC by local pathology review
Pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer
Pathologically proven diagnosis of any of the following malignancies:
Patients with biopsy proven locoregional recurrence or second primary SCCHN which is unresectable or the patient is unwilling to undergo resection
Subjects must have proven pediatric cancer with confirmation at diagnosis or at the time of recurrence/progression and clinical determination of disease for which there is no known effective curative therapy or disease that is refractory to established proven therapies fitting into one of the following categories:
Histologically or cytologically proven diagnosis of prostate cancer, sqNSCLC, TNBC, or known PTEN-deficient solid malignancy, and is refractory to standard therapies.
Histologically proven recurrent or residual intracranial or metastatic meningioma or meningioma with extracranial spread
History of clinically significant glomerulonephritis, biopsy-proven tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies.
Pathologically proven metastatic solid tumor (non-hematologic malignancy) of the bone (spine or non-spine bone)
Participants must have a biopsy-proven tumor consistent with small cell lung cancer and intracranial lesions radiographically consistent with or pathologically proven to be brain metastases; patients who have undergone prior systemic therapy are eligible
Participants must have a biopsy proven solid malignancy with untreated (by radiation) intracranial lesions radiographically consistent with or pathologically proven to be brain metastases; patients who have undergone prior systemic therapy are eligible
Biopsy proven confirmation of relapsed disease.
biopsy-proven refractory disease after frontline chemo-immunotherapy
Patients must have pathologically or cytologically proven transitional cell carcinoma (TCC) of the urothelium
Patients with pathologically proven nodal disease
Proven hypersensitivity to statins
Histologically or cytologically proven diagnosis of breast cancer with evidence of metastasis.
Pathologically-proven diagnosis of a solid tumor malignancy
biopsy-proven refractory disease after frontline chemo-immunotherapy
Any patient with a biopsy proven diagnosis of chondrosarcoma that is grade I, II or III or
Biopsy proven T malignant melanoma
Oligometastatic disease or unresectable primary abdominal malignancy with biopsy-proven primary disease histology of solid tumor categorization; patients with a diagnosis of hepatocellular carcinoma do not require a biopsy
Pathologically proven diagnosis of breast cancer
Diagnosis of localized breast, uterine or cervical cancer that is either biopsy proven or suspected based on history, physical, and/or radiographic findings, and who are planned for definitive resection of the tumor without the use of neoadjuvant chemotherapy or radiation therapy at Thomas Jefferson University Hospital (TJUH) are eligible to participate
Histologically or cytologically-proven T- or B-cell lymphoma
Biopsy-proven diagnosis of rectal adenocarcinoma
Documented or pathologically-proven metastatic disease
Patients do not need a histologically proven diagnosis of brain mets
Histologically or genetically proven unilateral primary or metastatic active pleural malignancy
Patients with known (biopsy proven) invasive carcinoma in a potential study polyp
Diagnosis of secondary Haemophagocytic Lymphohistiocytosis consequent to a proven rheumatic or neoplastic disease.
Any clinical or radiographically suspicious nodes, unless biopsy proven benign.
Histologically-proven, invasive primary carcinoma of the cervix
Pathologically (histologically) proven diagnosis of prostatic adenocarcinoma
Histologically proven non-Hodgkins lymphoma
Histologically proven rectal cancer
Biopsy proven ccRCC
Pathologically (histologically or cytologically) or radiographically-proven (based on the American Association for the Study of Liver Diseases [AALSD] criteria) unresectable or locally recurrent hepatocellular cancer prior to registration
Patients must have biopsy-proven adenocarcinoma of the small bowel at any site (duodenum, jejunum, ileum), excluding ampullary and appendiceal tumors
Histologically or cytologically proven diagnosis of hematologic malignancies for whom all standard therapy options have failed
Pathologic proven diagnosis of solid tumor malignancy
Histologically proven malignant solid tumors with measurable disease (except lymphomas)
Biopsy proven locally advanced breast cancer: IIB, IIIA and IIIB
Histologically proven adrenocortical carcinoma (ACC) with the majority of disease confined to the peritoneal cavity and resectable or amenable to radiofrequency ablation
Biopsy proven NSCLC
Pathologically proven diagnosis of endometrial or cervical cancer
Pathologic proven diagnosis of solid tumor malignancy
Patients with histologically proven HL will be eligible for transplantation after failing prior therapy
Histologically proven MCC
Pathologically proven diagnosis of NSCLC
Histologically or cytologically proven metastatic breast cancer (metastases can be proven with imaging results in certain circumstances provided that the initial tumor was demonstrated histologically)
Patients with biopsy proven NRSTS or bone sarcoma
Biopsy proven breast carcinoma which is persistent and metastatic or recurrent and metastatic.
Patients must have biopsy-proven metastatic MCC or locoregional MCC that has recurred following standard locoregional therapy with surgery and/or radiation therapy
The cancer that has no proven effective therapy
Histologically or cytologically proven diagnosis of prostate cancer.
Group B:\r\n* Newly diagnosed patient with histologically proven Ewing sarcoma family of tumor involving the bone or soft tissue and at least one of the following:\r\n** Metastatic disease (must be biopsy proven)\r\n** Pelvic primary\r\n** Age >=  years at the time of diagnosis\r\n*** Patients with more than one pulmonary lesion > cm may be considered as having evidence of metastatic disease without biopsy, as long as there is no other clear medical reason for these lesions; these cases should be discussed with the principal investigator (PI) and if there is any doubt, a biopsy should be obtained\r\n* Newly diagnosed patients with intra-abdominal, unresectable or metastatic desmoplastic small round cell tumor; metastatic site must be biopsy proven
Histologically proven solid tumor malignancy with metastasis to the spine; diagnosis may be acquired from needle biopsy, cytology, or surgical biopsy or resection
Histologically or cytologically proven prostate carcinoma
Patients with a pathologically proven diagnosis of NSCLC and consented to receive CXRT at MD Anderson
If patient has only one metastatic lesion/focus, this must be proven by biopsy and the pathology report confirming the diagnosis of primary breast cancer, as well as the metastatic site, must be available
Histologically or cytologically proven diagnosis of unresectable B thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)
Histologically proven non-Hodgkins lymphoma
Biopsy-proven, invasive carcinoma of the cervix
The cancer has no proven effective therapy
Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma (IHC) without distant extrahepatic metastasis within  days of registration; patients with an adenocarcinoma suggestive of a pancreaticobiliary primary with radiographic findings consistent with an intrahepatic cholangio-carcinoma are eligible
Histologically or cytology proven pancreatic ductal carcinoma
Patients must have histologically proven breast cancer with metastatic disease to the brain
Patients with a history of proven myocarditis, pericarditis, or endocarditis
Oligometastatic or unresectable primary disease planned for SBRT with biopsy-proven primary disease histology of solid tumor categorization with the exception of small cell cancers; hepatocellular carcinoma does not need to be biopsy proven if imaging and clinical findings are consistent with the diagnosis
An interval of at least  weeks after last dose of radiation and temozolomide is required, unless cancer progression is proven by diagnostic tumor biopsy. If temozolomide is being used in a maintenance phase, there must be a -day washout period prior to Randomization.
Pathologic proven diagnosis of solid tumor malignancy
Patients with a known history of proven myocarditis, pericarditis, and/ or endocarditis
Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or lung metastases (which are not required to be biopsy-proven) treated with definitive intent
Biopsy-proven differentiated VIN;
PATIENT: Biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma, cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year
Biopsy proven sarcoma located in the extremities
A probability of % or higher of a lung lesion being malignant as calculated by Bayesian analysis derived from clinical and radiographic criteria or, alternatively, biopsy proven disease
Biopsy-proven endometrial cancer
The effusion is an exudate (per Light's criteria) in the context of histocytologically proven malignancy elsewhere, with no other clear cause for fluid identified.
Serum creatinine < . x ULN unless due to biopsy proven CLL kidney infiltration
Patients with a pathologically proven diagnosis of CRC seen either at MD Anderson or Lyndon B Johnson General Hospital (LBJ)
Subjects with pathologically-proven gynecologic malignancies
Subjects with history of presumed or proven invasive fungal infection within  days of randomization
History of proven influenza disease after September , 
FOR THE  SUBJECTS ENROLLED IN YEAR : History of proven influenza disease after September , 
History of proven influenza disease after September , 
Proven, probable or possible IFI within the previous  days
Has a proven or probable invasive fungal infection
Participants with biopsy proven metastatic disease (M)
Subject has biopsy-proven multifocal breast cancer
Biopsy proven diagnosis or clinical diagnosis of any benign oral cavity lesion; pre-surgical biopsy will not be required if lesion is suspected to be benign
Biopsy proven diagnosis or clinical diagnosis of premalignant oral cavity lesions (leukoplakia, erythroplakia, lichen planus, dysplasia); pre-surgical biopsy will not be required if lesion is suspected to be benign
Patients with biopsy-proven breast cancer
Patient with lung cancer (presumed or biopsy proven) undergoing evaluation for resection
Pathologically (histologically or cytologically) proven diagnosis of cervical, vulvar, esophageal and anal canal cancer
Diagnosis of biopsy-proven invasive breast cancer measuring at least . cm in diameter by any imaging modality
Patients who have had surgical intervention or radiation for the current biopsy-proven malignancy
Patients with biopsy-proven extra-abdominal desmoid tumors
Biopsy proven HER negative primary breast cancer and biopsy proven metastatic disease
Suspected or known biopsy-proven malignancy (BI-RADS [R] category  & )
Adult, non-pregnant patients with biopsy-proven or clinically obvious primary, recurrent or metastatic breast cancer
Pathologically (histologically or cytologically) proven diagnosis of carcinoma
Primary tumor . cm or greater, and/or clinical evidence of axillary disease (palpable N or N or biopsy proven)
Biopsy proven Kaposis sarcoma involving the skin or mucosa
Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination
Patients who have histologically proven transitional cell carcinoma (TCC); or
Biopsy proven or clinically suspected advanced parenchymal liver disease
Patients must have histologically or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease.